Sino Biopharma receives exclusive rights to develop and commercialize two Ambrx enabled drug products in China Ambrx receives upfront payment plus undisclosed milestone payments and royalties.
SAN DIEGO, USA and BEIJING, China, January 12, 2020 – Ambrx Inc., a clinical-stage
biopharmaceutical company focused on the development of next generation biologics using
an expanded genetic code and Sino Biopharmaceutical Limited (1177.HK), a leading Chinese
pharmaceutical company with a large number of medical products covering multiple therapeutic
areas, announced a joint collaboration to develop two products enabled by Ambrx’s unique
non-natural amino acid incorporation technology platforms.
Under the agreement, Ambrx received an upfront payment to create two innovative drug
candidates, with Sino Biopharma then leading IND enabling activities for both China and
the US. The parties will jointly develop the programs to world-class standards with Sino
Biopharma commercializing the products within the greater China area and Ambrx
commercializing the products rest-of-world. Ambrx is eligible to receive additional
milestone payments for development, regulatory, and sales-based events, as well as
tiered royalties on future sales.
“We are delighted to join forces with Ambrx, a leader in precision engineered biologics
and breakthrough protein therapeutics, to develop two next generation cancer drugs”
commented Stephen Hsin Tse, Executive Director of Sino Biopharma. “This
collaboration helps fulfill our strong commitment to develop and commercialize
innovative biological drugs for the China market.”
The collaboration combines Ambrx’s clinically validated ReCODE™ and EuCODE™
platforms with Sino Biopharma’s strong resources and commitment to bring nextgeneration
biologic drugs to market.
“Sino Biopharma is a large, unique and fast-growing powerhouse in the Chinese
pharmaceutical industry, combining strong drug development expertise with substantial
commercial resources and infrastructure. We are delighted to collaborate with Sino
Biopharma as we continue to push the boundaries of next generation biologics with our
proprietary technologies.” said Feng Tian, Ph.D., President and CEO of Ambrx. “We are
very excited about the future of these two novel first-in-class and best-in-class drug
candidates and look forward to working with Sino Biopharma to unleash the therapeutic
potential of those drug candidates.”
About Sino Biopharmaceutical Limited (1177.HK)
Sino Biopharmaceutical Limited was listed on the Main Board of the Stock Exchange of
Hong Kong in 2003 and included as a constituent stock of the Hang Seng Index in
2018. Based on its sales in 2018, Sino Biopharma was ranked in July 2019 as one of
the top 50 pharmaceutical companies in the world by Pharmaceutical Executive
Magazine. Sino Biopharma principally engages in the research and development as
well as the manufacture and sales of pharmaceutical products. It is particularly
recognized for a range of medicines for treating liver diseases, tumors, cardio-cerebral
diseases, analgesia, respiratory system diseases and orthopedic diseases. For
additional information, visit www.sinobiopharm.com.
Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic
code to create best-in-class biotherapeutics, including antibody drug conjugates
(ADCs), targeted immunomodulators, bispecific antibodies and other novel biologics
with improved pharmacologic properties or novel biological activity. Leveraging the
Ambrx proprietary technology platforms, Ambrx has collaborations with Bristol-Myers
Squibb, Astellas, BeiGene, Elanco and ZMC, with drug products generated using Ambrx
technology in different stages of clinical trials. Ambrx is advancing a robust portfolio of
product candidates that are optimized for efficacy, safety and ease of use in multiple
therapeutic areas. For additional information, visit 39TUwww.ambrx.com.